New OIG work plan updates spotlight rising lab costs, compounded GLP-1 risks, and increased scrutiny on Medicaid and NIH oversight.
The latest updates from the Office of Inspector General provide a clear signal of where enforcement and oversight efforts are heading. For compliance teams, these updates offer critical insight into emerging risks, and an opportunity to proactively adjust audit and compliance strategies.
What’s New:
1. Medicare Laboratory Spending Under Review
Medicare Part B lab spending reached $8.4 billion in 2024, with a growing shift toward high-cost genetic testing. The OIG will continue analyzing the top 25 lab tests by expenditure, offering insight into utilization trends and potential areas of concern.
2. Ongoing Medicaid Lab Audit Series
A multi-project audit series is underway to assess whether states are complying with federal payment limits for outpatient laboratory services. Findings could have implications for reimbursement practices and state-level oversight.
3. Compounded GLP-1 Drugs Under Scrutiny
As demand for GLP-1 medications surged, compounding activity expanded during drug shortages. Now, the OIG is evaluating how effectively the FDA oversees these products, particularly as shortages have eased but compounding continues.
4. NIH Grant Oversight Expectations
The OIG is assessing how well NIH grant recipients manage and monitor subrecipients. With billions in funding at stake, organizations must ensure strong controls to prevent fraud, waste, and abuse.
These updates reinforce a common theme: increased scrutiny on high-cost services, third-party oversight, and areas where governance gaps can lead to compliance risk.